Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates.

Trinity College, Duke University, Durham, NC, USA.
Bulletin of the World Health Organisation (Impact Factor: 5.11). 02/1999; 77(10):801-7.
Source: PubMed

ABSTRACT Thousands of millions of injections are delivered every year in developing countries, many of them unsafe, and the transmission of certain bloodborne pathogens via this route is thought to be a major public health problem. In this article we report global and regional estimates of the number of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections that may occur from unsafe injections in the developing world. The estimates were determined using quantitative data on unsafe injection practices, transmission efficiency and disease burden of HBV, HCV and HIV and the prevalence of injection use obtained from a review of the literature. A simple mass-action model was used consisting of a generalized linear equation with variables accounting for the prevalence of a pathogen in a population, susceptibility of a population, transmission efficiency of the pathogen, proportion of injections that are unsafe, and the number of injections received. The model was applied to world census data to generate conservative estimates of incidence of transmission of bloodborne pathogens that may be attributable to unsafe injections. The model suggests that approximately 8-16 million HBV, 2.3-4.7 million HCV and 80,000-160,000 HIV infections may result every year from unsafe injections. The estimated range for HBV infections is in accordance with several epidemiological studies that attributed at least 20% of all new HBV infections to unsafe injections in developing countries. Our results suggest that unsafe injections may lead to a high number of infections with bloodborne pathogens. A major initiative is therefore needed to improve injection safety and decrease injection overuse in many countries.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Globally, hepatitis B is a significant health problem leading to one million deaths annually from liver failure, cirrhosis and hepatocellular carcinoma. It is estimated that 400 million people worldwide are hepatitis B virus (HBV) carriers. HBV infection is an important cause of morbidity and mortality after kidney transplantation. Progressive liver diseases affect more than 80% of hepatitis B surface antigen (HBsAg) in positive renal transplant recipients. The natural history of HBV infection is complex, which is influenced by many factors such as viral factors which includes HBV genome type, viral mutations, level of HBV replication and host factors such as gender, age and immune status. It is also influenced by exogenous factors such as concurrent infection with other viruses, most notably HIV and hepatitis C virus. Dual infection can modify the epidemiology, natural history and the development of complications of infection. The management of dually infected patients also varies from that of HBV mono infected patients. The implementation of mass immunization programme has considerably decreased the incidence of HBV infection among infants, children and adolescents across the world. But the immune response varies with individual and declines with increasing age. Despite, the prevention of hepatitis B virus infection by vaccination programme, the infection is still prevalent worldwide. Treatment with antiviral drugs is the major way to reduce morbidity and mortality of established chronic hepatitis B virus infection. Drugs like adefovir, entecavir, telbivudine, lamivudine & interferon a 2a has been approved for the treatment of chronic hepatitis B. The ultimate aim of anti viral therapy is to suppress viral replication, reduce the liver inflammation, reverse the liver fibrosis and thereby protect the liver. Even though antiviral drugs are effective but drug resistance remains a global public health problem.
    Journal of Pharmacy Research 12/2014; 2014(8(11)):2014. · 2.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Hepatitis B virus (HBV) is a potentially life-threating infection and a well-recognized occupational hazard for health-care workers including medical students. Methods. A cross-sectional study was conducted at Syrian Private University (SPU), Faculty of Medicine, to assess the knowledge and awareness about hepatitis B, the status of hepatitis B vaccination, and the reasons for not getting vaccinated among the first- and the fifth-year medical students. Results. The present study demonstrates surprising results and raises issues about the high number of medical students that are not vaccinated or not sure about their vaccination status, which puts them at a higher risk of being infected in the future. Another important issue is the medical students’ overall knowledge about this life-threating infection. The students have not been totally educated about the gravity of the situation which requires the need of further HBV education. It is highly recommended that SPU provides the HBV vaccine to all nonvaccinated students attending the faculty of medicine at no cost to encourage them to take the HBV vaccine and to reform some of its educational curriculum to effectively limit the hazardous effects of this disease and elaborate on the serious health consequences of HBV
    Hepatitis research and treatment 11/2014; 2014.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis B virus infection is a significant health problem. Approximately two billion people worldwide have chronic Hepatitis B virus infection and over one million die annually. Hepatitis B virus infection and Human Immunodeficiency Virus co-infection is an emerging concern in the clinical management of patients because of shared routes of transmission. Hospital based cross-sectional study was performed from January to June, 2012 at Goba General Hospital. Socio-demographic and possible risk factors data from study subjects were collected using pre-test and structured questionnaire. Venous blood was collected and the serums were tested for Hepatitis B surface antigen and Human Immune Deficiency Virus using commercially available rapid test kits. Data were entered and analyzed using the SPSS software package (version15). Binary and multivariable logistic regressions were used to identify factors associated factors. A p-value of <0.05 was considered statistical significant. The prevalence of Hepatitis B surface Antigen in this study group was 26 (7.4%). Prevalence of Hepatitis B Human Immune Deficiency Virus Co-infection was about 9 (42.3%) and about 17 (5.1%) of Human Immuno Deficiency Virus negative subjects were positive for Hepatitis B surface Antigen. Risk factors like, hospital admission, multiple sexual partners, HIV status, and unsafe drug injection were found to have significant association with Hepatitis B surface Antigen on binary logistic regression. However, multiple sexual partners and being positive for Human Immuno Deficiency Virus infection were the only significantly associated with Hepatitis B Virus on multivariable logistic regression. Even though Hepatitis B surface Antigen prevalence is higher among subjects who are Human Immuno Deficiency Virus positive, screening program has to be started in the hospital for all clients regardless of their disease status to prevent the potential spread of the infection.
    BMC Research Notes 01/2014; 7:833.

Full-text (2 Sources)

Available from
Jul 16, 2014